1
van Hulst, Marinus, Hubben, Gijs A. A., Sagoe, Kwamena W. C., Promwong, Charupon, Permpikul, Parichart, Fongsatitkul, Ladda, Glynn, Diarmuid M., Smit Sibinga, Cees T., Postma, Maarten J.
Veröffentlicht in: van Hulst , M , Hubben , G A A , Sagoe , K W C , Promwong , C , Permpikul , P , Fongsatitkul , L , Glynn , D M , Smit Sibinga , C T & Postma , M J 2009 , ' Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening : a global model applied to Ghana, Thailand, and the Netherlands ' , Transfusion , vol. 49 , no. 12 , pp. 2729-2742 . https://doi.org/10.1111/j.1537-2995.2009.02351.x;
2009
Veröffentlicht in: van Hulst , M , Hubben , G A A , Sagoe , K W C , Promwong , C , Permpikul , P , Fongsatitkul , L , Glynn , D M , Smit Sibinga , C T & Postma , M J 2009 , ' Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening : a global model applied to Ghana, Thailand, and the Netherlands ' , Transfusion , vol. 49 , no. 12 , pp. 2729-2742 . https://doi.org/10.1111/j.1537-2995.2009.02351.x;
2009
2
Hubben, Gijs A A, Bos, Jasper M, Veltman-Starkenburg, Christa A, Stegmeijer, Simon, Finnern, Henrik W, Kappelhoff, Bregt S, Simpson, Kit N, Tramarin, Andrea, Postma, Maarten J
Veröffentlicht in: Hubben , G A A , Bos , J M , Veltman-Starkenburg , C A , Stegmeijer , S , Finnern , H W , Kappelhoff , B S , Simpson , K N , Tramarin , A & Postma , M J 2007 , ' Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands ' , Cost Effectiveness and Resource Allocation , vol. 5 , pp. 15 . https://doi.org/10.1186/1478-7547-5-15;
2007
Veröffentlicht in: Hubben , G A A , Bos , J M , Veltman-Starkenburg , C A , Stegmeijer , S , Finnern , H W , Kappelhoff , B S , Simpson , K N , Tramarin , A & Postma , M J 2007 , ' Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands ' , Cost Effectiveness and Resource Allocation , vol. 5 , pp. 15 . https://doi.org/10.1186/1478-7547-5-15;
2007